Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New insight into tumor biology

Cancer cells are well known for their altered metabolisms, which may help them generate the energy they need for rapid growth. Using an emerging imaging technology, researchers reporting in the July Cell Metabolism, a Cell Press publication, have discovered that those metabolic shifts actually develop even before detectable tumors form.

6 Jul 2011

Medicare to cover 2 expensive cancer drugs

Medicare confirmed on Thursday that it would continue to pay for two expensive cancer drugs that had been at the center of debate — Avastin from Genentech for breast cancer and Provenge from Dendreon for prostate cancer.

2 Jul 2011

First Edition: July 1, 2011

Today's early morning highlights from the major news organizations, including reports about sleep deprived medical residents, decisions by Medicare officials on covering two expensive drugs and states struggling with budget cuts.

1 Jul 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on August 10, 2011 to discuss the CMC, pharmacology, toxicology, and clinical plans for Advaxis PSA, its construct to fight prostate cancer.

1 Jul 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

GenSpera, Inc. has entered into a cooperation agreement with the University of Copenhagen, in Copenhagen, Denmark, to collaborate on the "SPOTLight" (Sustainable Production of Thapsigargin using Light) project.

29 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

New prostate cancer drugs bring cost of care into spotlight

Meanwhile, results from a three-decade Swedish study found that women who have mammograms have a lower death rate from breast cancer — a finding that some say may ease recent controversies around the screening procedure.

29 Jun 2011

First Edition: June 28, 2011

Today's headlines include reports from the states about action on public employee benefit reforms and Planned Parenthood funding.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

CANCER RESEARCH UK Cancer Research UK scientists have discovered why a sub group of oestrogen-receptor-negative breast cancer patients could benefit from prostate cancer treatments which target the cell's androgen receptor - a key driver of prostate cancer, according to research published in The EMBO Journal today.

27 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients, according to a study in the July issue of the urology journal BJUI.

22 Jun 2011

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation named five new Damon Runyon Clinical Investigators at its spring 2011 Clinical Investigator Award Committee review.

22 Jun 2011

Smoking may increase risk of death from prostate cancer

Men who are diagnosed with prostate cancer and who are also smokers have an associated increased risk of all-cause, cardiovascular and prostate cancer-specific death, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Prostate cancer risk and prevention

According to U.S. researchers smoking increases the risk that men who develop prostate cancer will die from their disease. The longer the men smoked, the greater the risk, said Stacey Kenfield of the Harvard School of Public Health in Boston, whose study appears in the Journal of the American Medical Association. Prostate cancer is the second-leading cause of cancer death in men behind lung cancer

22 Jun 2011

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

A yet unidentified component of coffee interacts with the beverage's caffeine, which could be a surprising reason why daily coffee intake protects against Alzheimer's disease.

22 Jun 2011

Panacea Global announces name change

Panacea Global Inc.,, a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.

20 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New insight into tumor biology

Medicare to cover 2 expensive cancer drugs

First Edition: July 1, 2011

FDA grants Advaxis pre-IND meeting for Advaxis-PSA immunotherapy for prostate cancer

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

GenSpera and University of Copenhagen collaborate on 'Sustainable Production of Thapsigargin using Light'

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

New prostate cancer drugs bring cost of care into spotlight

First Edition: June 28, 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Prostate cancer therapy may benefit patients with oestrogen-negative breast cancer

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Homosexual men with prostate cancer more likely to report problems with bicalutamide drug

Nine young clinical investigators earn recognition from Damon Runyon Cancer Research Foundation

Smoking may increase risk of death from prostate cancer

Prostate cancer risk and prevention

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

Panacea Global announces name change

IsoRay announces combination therapy study for prostate cancer

What to know about prostate cancer eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in